Article Details

AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition

Retrieved on: 2024-03-25 21:08:53

Tags for this article:

Click the tags to see associated articles and topics

AbbVie Gets Another Ulcerative Colitis Contender via $137M Landos Acquisition. View article details on hiswai:

Excerpt

AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis.

Article found on: medcitynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo